<DOC>
	<DOC>NCT00757627</DOC>
	<brief_summary>The purpose of this study is to collect disease burden of OA and the effectiveness and patient satisfaction of treatment by Etoricoxib in the normal practice setting.</brief_summary>
	<brief_title>Patient-Reported Effectiveness and Safety of Etoricoxib in Osteoarthritis (OA)(0663-113)</brief_title>
	<detailed_description />
	<mesh_term>Etoricoxib</mesh_term>
	<criteria>Must Be Over 20 Years Of Age, Regardless Of Sex Must Have A Diagnosis Of OA That Requiring Treatment Patients Must Have Taken an NSAID, Cox2 Or Opioids On The Majority Of Days During The Last 4 Weeks Before Enrollment Who Are Intolerant (Due To Gastrointestinal Adverse Events) Or Inadequately Respond To Current Therapy (Vas &gt;= 40 mm On A Pain Scale From 0100 mm) Excluding Osteoarthritis, The Patient Is Judged To Be In Otherwise General Good Health Based On Medical History, Physical Examination, And Routine Laboratory Tests Must Agree To Participate Voluntarily In The Study Must Have The Capacity To Understand And Answer The Questionnaires Used In The Study Must Agree To Return For A FollowUp Visit With The Treating Physician Four Weeks After The Initiation Of Treatment With Etoricoxib Patient Is Willing To Sign Informed Consent Form Under 20 Years Of Age Severe Hepatic Insufficiency (ChildPugh Score &gt; 9) Advanced Renal Insufficiency (Creatinine Clearance &lt; 30 Ml/Min) Any Contraindication Or Warning Or Precaution As Mentioned In The Approved Study Drug Package Insert Gi Ulcer With Active Bleeding Present At Study Enrollment Patient Has A Recent History Of Stroke, Myocardial Infarction Or Transient Ischemic Attack (Within The Previous 2 Years)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>